TY - JOUR
T1 - Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis
AU - Tasset, Inmaculada
AU - Bahamonde, Carmen
AU - Agüera, Eduardo
AU - Conde, Cristina
AU - Cruz, Antonio H.
AU - Pérez-Herrera, Aleyda
AU - Gascón, Félix
AU - Giraldo, Ana I.
AU - Ruiz, María C.
AU - Lillo, Rafael
AU - Sánchez-López, Fernando
AU - Túnez, Isaac
PY - 2013
Y1 - 2013
N2 - Background: Natalizumab is a monoclonal antibody used to treat multiple sclerosis. This study sought to determine whether the protective action of natalizumab involved a reduction in oxidative damage. Methods: Twenty-two multiple sclerosis patients fulfilling the revised McDonald criteria were assigned to treatment with 300 mg natalizumab intravenously once monthly (infusion every 4 weeks) in accordance with Spanish guidelines. Carbonylated proteins, 8-hydroxy-2'-deoxyguanosine, total glutathione, reduced glutathione, superoxide dismutase, glutathione peroxidase, and myeloperoxidase levels were measured at baseline and after 14 months' treatment, and the antioxidant gap was calculated. Results: Natalizumab prompted a drop in oxidative-damage biomarker levels, together with a reduction both in myeloperoxidase levels and in the myeloperoxidase/neutrophil granulocyte ratio. Interestingly, natalizumab induced nuclear translocation of Nrf2 and a fall in serum vascular cell adhesion molecule-1 levels. Conclusion: These findings suggest that natalizumab has a beneficial effect on oxidative damage found in MS patients.
AB - Background: Natalizumab is a monoclonal antibody used to treat multiple sclerosis. This study sought to determine whether the protective action of natalizumab involved a reduction in oxidative damage. Methods: Twenty-two multiple sclerosis patients fulfilling the revised McDonald criteria were assigned to treatment with 300 mg natalizumab intravenously once monthly (infusion every 4 weeks) in accordance with Spanish guidelines. Carbonylated proteins, 8-hydroxy-2'-deoxyguanosine, total glutathione, reduced glutathione, superoxide dismutase, glutathione peroxidase, and myeloperoxidase levels were measured at baseline and after 14 months' treatment, and the antioxidant gap was calculated. Results: Natalizumab prompted a drop in oxidative-damage biomarker levels, together with a reduction both in myeloperoxidase levels and in the myeloperoxidase/neutrophil granulocyte ratio. Interestingly, natalizumab induced nuclear translocation of Nrf2 and a fall in serum vascular cell adhesion molecule-1 levels. Conclusion: These findings suggest that natalizumab has a beneficial effect on oxidative damage found in MS patients.
KW - Adhesion molecules
KW - Multiple sclerosis
KW - Natalizumab
KW - Nrf2
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=84884495677&partnerID=8YFLogxK
U2 - 10.1016/S1734-1140(13)71039-9
DO - 10.1016/S1734-1140(13)71039-9
M3 - Artículo
SN - 2299-5684
VL - 65
SP - 624
EP - 631
JO - Pharmacological Reports
JF - Pharmacological Reports
IS - 3
ER -